
RANI Stock Forecast & Price Target
RANI Analyst Ratings
Bulls say
Rani Therapeutics Holdings Inc. is advancing its proprietary RaniPill capsule technology, which enables the oral delivery of a wide range of biologics, including antibodies and peptides, providing a less painful alternative to injections. The company has demonstrated promising preclinical results, with plans to proceed to Phase 1c trials for obesity treatment, indicating progress and potential in tapping into the lucrative multi-billion dollar obesity market. Additionally, Rani's strategic collaborations, such as with ProGen, enhance its capacity to develop various obesity programs, solidifying its position in a competitive landscape while leveraging its innovative delivery platform.
Bears say
Rani Therapeutics Holdings Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to competitive pressures and regulatory uncertainties. The presence of several companies developing long-acting injectable formulations could diminish the market share and competitive advantage of the RaniPill, while management turnover may disrupt clinical development timelines, further impacting investor confidence. Additionally, risks associated with negative clinical trial outcomes, potential delays in receiving FDA approvals, and weak market adoption of Rani's products compound the uncertainties surrounding the company's future financial performance.
This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.
RANI Analyst Forecast & Price Prediction
Start investing in RANI
Order type
Buy in
Order amount
Est. shares
0 shares